Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers

Environmental Health Perspectives

Volumn 112, Issue 15, 2004, Pages 1512-1518

  Satarug, Soisungwan ^a   Nishijo, Muneko ^b   Ujjin, Pailin ^c   Vanavanitkun, Yuvaree ^c   Baker, Jason R ^d   Moore, Michael R ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d FLINDERS UNIVERSITY   (Australia)

^e QUEENSLAND HEALTH   (Australia)

Author keywords

2 microglobulin; Cadmium; Coumarin; Cytochrome P450 2A6; Drug metabolizing enzyme; Environmental exposure; Lead; Liver drug metabolism; N acetyl D glucosaminidase; Nicotine; Nicotine C oxidase; Proteinuria; Zinc

Indexed keywords

BIOLOGICAL MARKER; CADMIUM; CREATININE; CYTOCHROME P450 2A6; LEAD; N ACETYL BETA GLUCOSAMINIDASE; ZINC;

AGE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED MEDICINE; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; URINARY EXCRETION; ZINC BLOOD LEVEL; ZINC URINE LEVEL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CADMIUM; CADMIUM POISONING; DIET; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; KIDNEY; LEAD; LEAD POISONING; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; SEX FACTORS; TISSUE DISTRIBUTION; ZINC;

EID: 8744262844     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.7192     Document Type: Article

References (57)

1. Abu-Bakar A, Satarug S, Marks G, Lang MA, Moore MR. 2004. Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: involvement of the transcription factor Nrf2. Toxicol Lett 148:199-210.
2. Alam J, Shibahara S, Smith A. 1989. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J Biol Chem 264:6371-6375.
3. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S. 2000. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. J Biol Chem 275:27694-27702.
4. Baker JR, Satarug S, Reilly PEB, Edward RJ, Ariyoshi N, Kamataki T, et al. 2001. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples. Biochem Pharmacol 62:713-721.
5. Baker JR, Satarug S, Urbenjapol S, Edward RJ, Williams DJ, Moore MR, et al. 2002. Associations between human liver and kidney cadmium content and immunochemically detected CYP4A11 apoprotein. Biochem Pharmacol 63:693-696.
6. Baker JR, Satarug S, Urbenjapol S, Edward RJ, Williams DJ, Moore MR, et al. 2003. Potential for early involvement of CYP isoforms in aspects of human cadmium toxicity. Toxicol Lett 137:85-93.
7. Bartosiewicz MJ, Jenkins D, Penn S, Emery J, Buckpitt A. 2001. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J Pharmacol Exp Ther 297:895-905.
8. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P III. 2003. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 5:621-624.
9. Bhatnagar A. 2004. Cardiovascular pathophysiology of environmental pollutants. Am J Physiol Heart Circ Physiol 286:H497-H485.
10. Buchet JP, Lauwerys R, Roels H, Bernard A, Bruaux P, Claeys F, et al. 1990. Renal effects of cadmium body burden of the general population. Lancet 336:699-702.
11. Custer EM, Finch CA, Sobel RE, Zettner A. 1995. Population norms for serum ferritin. J Lab Clin Med 126:88-94.
12. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H. 2000. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 28:1321-1326.
13. Fischbein A, Alvares AP, Anderson KE, Sassa S, Kappas A. 1977. Lead intoxication among demolition workers: the effect of lead on the hepatic cytochrome P-450 system in humans. J Toxicol Environ Health 3:431-437.
14. Fujita H. 1997. Molecular mechanism of heme biosynthesis. Tohoku J Exp Med 183:83-99.
15. Furst A. 2002. Can nutrition affect chemical toxicity? Intl J Toxicol 21:419-424.
16. Galal-Gorchev H. 1993. Dietary intake, levels in food and estimated intake of lead, cadmium and mercury. Food Addit Contam 10:115-128.
17. Goyer RA. 1997. Toxic and essential metal interactions. Annu Rev Nutr 17:37-50.
18. Ikeda M, Zhang Z-W, Moon C-S, Shimbo S, Watanabe T, Nakatsuka N, et al. 2000. Possible effects of environmental cadmium exposure on kidney function in the Japanese general population. Int Arch Environ Health 73:15-25.
19. IPCS (International Programme on Chemical Safety). 1992. Cadmium. Environmental Health Criteria 134. Geneva:World Health Organization.
20. Jarup L. 2002. Cadmium overload and toxicity. Nephrol Dial Transplant 17(suppl 2):35-39.
21. Jarup L, Berglund M, Elinder C, Nordberg G, Vahter M. 1998. Health effects of cadmium exposure-a review of literature and a risk estimate. Scand J Work Environ Health 24(suppl):1-52.
22. Jin T, Nordberg M, Frech W, Dumont X, Bernard A, Ye T, et al. 2002. Cadmium biomonitoring and renal dysfunction among a population environmentally exposed to cadmium from smelting in China (ChinaCad). Biometals 15:397-410.
23. Kraul H, Truckenbrodt J, Huster A, Topfer R, Hoffman A. 1991. Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. Eur J Clin Pharmacol 4:475-480.
24. Lauwerys RR, Bernard AM, Roels HA, Buchet JP. 1994. Cadmium: exposure markers as predictors of nephrotoxic effects. Clin Chem 40(7):1391-1394.
25. Madden EF, Fowler BA. 2000. Mechanisms of nephrotoxicity from metal combinations: a review. Drug Chem Toxicol 23:1-12.
26. Meredith PA, Campbell BC, Moore MR, Goldberg A. 1977. The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation. Eur J Clin Pharmacol 12:235-239.
27. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYHP2A6 in nicotine C-oxidation by human liver microsome. J Pharmacol Exp Ther 282:1608-1614.
28. Moore MR. 2004. A commentary on the impacts of metals and metalloids in the environment upon the metabolism of drugs and chemicals. Toxicol Lett 148:153-158.
29. Moore R, Goldberg A, Yeung-Laiwah AA. 1987. Lead effects on the heme biosynthetic pathway. Relationship to toxicity. Ann NY Acad Sci 514:191-203.
30. Mortada WI, Sobh MA, El-Defrawy MM, Farahat SE. 2001. Study of lead exposure from automobile exhaust as a risk for nephrotoxicity among traffic policemen. Am J Nephrol 21:274-279.
31. Mueller PW, Price RG, Finn WF. 1998. New approaches for detecting thresholds of human nephrotoxicity using cadmium as an example. Environ Health Perspect 106:227-230.
32. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. 1996. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
33. Nishijo M, Satarug S, Honda R, Tsuritani I, Aoshima K. 2004. The gender differences in health effects of environmental cadmium exposure and potential mechanisms. Mol Cell Biochem 255:87-92.
34. Noonan CW, Sarasua SM, Campagna D, Kathman SJ, Lybarger JA, Mueller PW. 2002. Effects of exposure to low levels of environmental cadmium on renal biomarkers. Environ Health Perspect 110:151-155.
35. Oo YK, Kobayashi E, Nogawa K, Kubo Y, Suwazono Y, Kido T, et al. 2000. Renal effects of cadmium intake in a Japanese general population in two areas unpolluted by cadmium. Arch Environ Health 55:98-103.
36. Oscarson M. 2001. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29:91-95.
37. Pasanen M, Rannala Z, Tooming A, Sotaniemi EA, Pelkonen O, Rautio A. 1997. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 123:177-184.
38. Pelkonen O, Rautio A, Raunio H, Pasanen M. 2000. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139-147.
39. Raunio H, Juvonen R, Pasanen M, Pelkonen O. 2001. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363.
40. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. 1992. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2:227-233.
41. Rosenberg DW, Kappas A. 1991. Induction of heme oxygenase in the small intestinal epithelium: a response to oral cadmium exposure. Toxicology 67:199-210.
42. Satarug S, Baker JR, Reilly PEB, Moore MR, Williams DJ. 2001. Changes in zinc and copper homeostasis in human livers and kidneys associated with exposure to environmental cadmium. Hum Exp Toxicol 20(4):205-213.
43. Satarug S, Baker JR, Reilly PEB, Moore MR, Williams DJ. 2002. Cadmium levels in the lung, liver, kidney cortex and urine samples from Australians without occupational exposure to metals. Arch Environ Health 57:69-77.
44. Satarug S, Haswell-Elkins MR, Moore MR. 2000. Safe levels of cadmium intake to prevent renal toxicity in human subjects. Br J Nutr 84:791-802.
45. Satarug S, Lang MA, Yongvanit P, Sithithaworn P, Mairiang E, Mairiang P, et al. 1996. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. Cancer Epidemiol Biomark Prev 5:795-800.
46. Satarug S, Nishijo M, Ujjin P, Vanavanitkun Y, Baker JR, Moore MR. 2004a. Effects of chronic exposure to low-level cadmium on renal function and CYP2A6-mediated coumarin metabolism in human subjects. Toxicol Lett 148:187-197.
47. Satarug S, Ujjin P, Vanavanitkun Y, Baker JR, Moore MR. 2004b. Influence of body iron store status and cigarette smoking on cadmium body burden of healthy Thai men and women. Toxicol Lett 148:177-185.
48. Satarug S, Ujjin P, Vanavanitkun Y, Mishijo M, Baker JR, Moore MR. 2004c. Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men. Toxicology 204(2-3):161-173.
49. Schoedel KA, Sellers EM, Palmour R, Tyndale RF. 2003. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63:96-104.
50. Sotaniemi EA, Raunio A, Backstrom M, Arvela P, Pelkonen O. 1995. CYP3A4 and CYP2A6 activities marked by the metabolism of ligocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 39:71-76.
51. Tenhunen R, Marver HS, Schmid R. 1968. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 61:748-755.
52. Tricker AR. 2003. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behavior. Toxicology 183:151-173.
53. Ujjin P, Satarug S, Vanavanitkun Y, Daigo S, Ariyoshi N, Yamazaki H, et al. 2002. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics 12:241-249.
54. Urbenjapol S, Satarug S, Noller B, Moore MR. 2001. Induction of the liver CYP2A5 in female BALB/c mice exposed to cadmium [Abstract]. Toxicology 164:62.
55. Vahter M, Berglund M, Akesson A, Liden C. 2002. Metals and women's health. Environ Res 88:145-155.
56. Walters DG, Lake BG, Cottrell RC. 1980. High performance liquid chromatography of coumarin and its metabolites. J Chromatogr 196:501-505.
57. World Health Organization, 1989. Evaluation of Certain Food Additives and Contaminants. WHO Technical Report Series No. 776. Geneva:World Health Organization.